The most frequently assessed tumor marker before first-line chemotherapy was the CEA level (82.9%), followed by the CYFRA (73.1%), SCC antigen (66.4%), ProGRP (58.0%), NSE (51.4%), and AFP levels (37.4%). This evidence concerns the gene CEACAM5 and neoplasm.